EMCN

EMCN Full Name

endomucin

EMCN Introduction

Emcn encodes endomucin (EMCN), a type I transmembrane sialomucin that is expressed with high specificity by venous and capillary endothelial cells, where it localizes to the apical (luminal) membrane surface. As a heavily O-glycosylated protein rich in serine, threonine, and sialic acid residues, EMCN adopts an extended, rigid rod-like conformation that projects from the endothelial surface into the vascular lumen. This topological and biochemical configuration enables EMCN to function as an anti-adhesive molecule that prevents excessive engagement of circulating leukocytes with the endothelial surface under both resting and inflammatory conditions. EMCN is absent from arterial endothelium, conferring a distinctive molecular signature that has been widely exploited as a venous- and capillary-specific endothelial marker in developmental, angiogenic, and tumor vascular research. During embryogenesis and early postnatal development, EMCN is dynamically expressed in sprouting endothelial tip cells, where it participates in vascular remodeling and the orchestration of new blood vessel formation.

Figure 1. Endomucin and developing HSCs. (Source: Matsubara A, et al. 2005)

EMCN modulates angiogenesis through its regulatory effect on vascular endothelial growth factor (VEGF) signaling. Experimental reduction of EMCN in vivo impairs developmental angiogenesis in the retina, accompanied by reduced endothelial cell migration, diminished tip cell formation, and attenuated VEGFR2 (KDR) phosphorylation. Conversely, EMCN overexpression potentiates VEGF-induced endothelial cell migration, proliferation, and tube morphogenesis in vitro, effects that are selective for VEGF signaling and not replicated by other angiogenic stimuli such as bFGF. At the molecular level, EMCN positively regulates VEGFR2 phosphorylation and downstream signaling through the ERK1/2, p38-MAPK, and Akt pathways, plausibly through interaction with heparan sulfate proteoglycans or galectins at the endothelial cell surface. Given its endothelial-restricted expression and functional importance in vascular development and pathological angiogenesis, EMCN represents a promising target for therapeutic strategies aimed at modulating angiogenesis in diseases ranging from ischemic disorders to cancer.

Alternate Names for EMCN

EMCN; endomucin; EMCN2; MUC14; MUC-14; mucin-14; endomucin-2; gastric cancer antigen Ga34;

View more

• 1. Matsubara A, et al. Endomucin, a CD34-like sialomucin, marks hematopoietic stem cells throughout development. J Exp Med. 2005 Dec 5;202(11):1483-92.
  2. Park-Windhol C, et al. Endomucin inhibits VEGF-induced endothelial cell migration, growth, and morphogenesis by modulating VEGFR2 signaling. Sci Rep. 2017 Dec 7;7(1):17138.